91 Ratings
Rs 2,860 Rs 2,200
23 % OFF
PROGESTERONE RECEPTOR (PR) IS A SURROGATE MARKER OF ESTROGEN RECEPTOR (ER) ACTIVITY IN THE MANAGEMENT OF WOMEN WITH BREAST CANCER. ER & PR STATUS PROVIDES AN INDICATION OF PROGNOSIS AND POTENTIAL BENEFIT FROM HORMONAL THERAPY. GENERALLY ER & PR POSITIVE TUMORS ARE MORE LIKELY TO RESPOND TO ENDOCRINE THERAPY AND HAVE A BETTER PROGNOSIS, STAGE FOR STAGE AS COMPARED TO RECEPTOR NEGATIVE TUMORS. THIS TEST IS RECOMMENDED IN PATIENTS WITH NEWLY DIAGNOSED BREAST CANCER AND METASTATIC & RECURRENT BREAST CANCER.
